济川药业增加实控人,君实生物布局猴痘疫苗,*ST苏吴面临财务类退市风险,睿智医药1500万元设立全资子公司

谈医说药
11 Jun

科伦药业:近日公司控股子公司科伦博泰获得国家药监局授予的突破性疗法认定,针对其核心产品芦康沙妥珠单抗(sac-TMT)联合塔戈利单抗一线治疗无驱动基因突变的局部晚期或转移性非鳞状非小细胞肺癌。这是芦康沙妥珠单抗获得的第五项突破性疗法认定,显示出其在治疗领域的临床优势。贝瑞基因:公司控股股东高扬先生在国信证券开展的股票质押回购业务发生违约,成渝金融法院裁定强制变现被执行人高扬先生持有的“贝瑞基因”...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10